Our Team

What began in 2013 as a start-up with a founding team of five key people has developed into a pharmaceutical company with its own GMP-certified Nanofactory and over 50 employees. With an experienced Board of Directors and a well-established management team, InnoMedica combines extensive know-how to successfully realize upcoming projects.

Today, the InnoMedica team consists of over 50 employees. InnoMedica's strong technical focus is reflected in a large number of employees with degrees in biochemistry, chemistry, biomedicine, or pharmacy. The high level of expertise in this core area is an important factor in InnoMedica's success

When recruiting, InnoMedica places a strong emphasis on the motivation and interests of its employees. Great importance is placed on employee participation with regard to their personal development within the company in order to fully develop their potential and enable internal promotion.

The Board of Directors of InnoMedica Holding AG ensures quick decisions and direct action. Thanks to the biochemical background of Dr. Noboru Yamazaki, the medical knowledge of MD Denis Bron, and the economic and entrepreneurial expertise of Prof. Dr. Urs Wälchli, the Board of Directors can rely on know-how from various areas. The active involvement of the members of the Board of Directors in individual projects ensures proximity to InnoMedica's operational activities. This is essential in order to take account of the dynamic nature of the company.

With the founding team of Dr. Stéfan Halbherr, Andrea Zurkirchen, Dr. Jonas Zeller, and Pascal Halbherr on the management board of InnoMedica Schweiz AG, the company benefits from an experienced and well-coordinated team for the efficient management of the company. In 2022, Dr. Camille Peitsch and in 2023, Dr. Martin Stähle joined the management board. As General Manager of InnoMedica Holding AG, Dr. Stéfan Halbherr takes over the management of the operational business. Andrea Zurkirchen is responsible for Communications, HR, and Legal & Compliance, while Dr. Jonas Zeller is in charge of Business Development. Pascal Halbherr is Head of Manufacturing and is therefore in charge of the operational processes at the Nanofactory in Marly. Dr. Camille Peitsch is responsible for Research, Development, and Sales, and Dr. Martin Stähle for Finance and Administration.